Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025)
Foghorn Therapeutics (FHTX) posted quarterly Asset Writedowns and Impairment of $5.9 million for Q4 2025, up 294900.0% year-over-year from N/an in Q4 2024, and up 294900.0% quarter-over-quarter from $2000.0 in Q4 2024.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Foghorn Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $5.9 million for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment rose 294900.0% year-over-year to $5.9 million; the TTM figure through Dec 2025 stood at $5.9 million (up 145.92% YoY), while the FY2025 annual figure was $5.9 million, up 145.83% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $5.9 million, up from $2000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $5.9 million in Q4 2025, with the low at $2000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5.91 Mn |
| Dec 31, 2024 | 2,000.00 |
| Jun 30, 2024 | 2.40 Mn |